PortfoliosLab logoPortfoliosLab logo
CRVS vs. ATEYY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CRVS vs. ATEYY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corvus Pharmaceuticals, Inc. (CRVS) and Advantest Corp DRC (ATEYY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CRVS achieves a 108.83% return, which is significantly higher than ATEYY's 40.43% return. Over the past 10 years, CRVS has underperformed ATEYY with an annualized return of 0.94%, while ATEYY has yielded a comparatively higher 53.11% annualized return.


CRVS

1D
2.88%
1M
44.22%
6M
126.48%
YTD
108.83%
1Y
306.06%
3Y*
83.79%
5Y*
44.41%
10Y*
0.94%

ATEYY

1D
0.80%
1M
7.18%
6M
34.56%
YTD
40.43%
1Y
134.13%
3Y*
71.39%
5Y*
51.82%
10Y*
53.11%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CRVS vs. ATEYY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CRVS
Corvus Pharmaceuticals, Inc.
108.83%43.93%203.98%107.06%-64.73%-32.30%-34.56%48.23%-64.58%-27.55%
ATEYY
Advantest Corp DRC
40.43%122.70%68.99%111.43%-33.43%27.37%30.96%176.84%12.51%12.66%

Correlation

The correlation between CRVS and ATEYY is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.26

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.16

Correlation (All Time)
Calculated using the full available price history since Mar 23, 2016

0.16

Fundamentals

Market Cap

CRVS:

$1.35B

ATEYY:

$128.70B

EPS

CRVS:

-$0.52

ATEYY:

¥520.91

PB Ratio

CRVS:

6.01

ATEYY:

26.31

Total Revenue (TTM)

CRVS:

$0.00

ATEYY:

¥1.14T

Gross Profit (TTM)

CRVS:

-$26.00K

ATEYY:

¥736.09B

EBITDA (TTM)

CRVS:

-$47.43M

ATEYY:

¥533.69B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CRVS vs. ATEYY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRVS
CRVS Risk / Return Rank: 9494
Overall Rank
CRVS Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
CRVS Sortino Ratio Rank: 9898
Sortino Ratio Rank
CRVS Omega Ratio Rank: 9797
Omega Ratio Rank
CRVS Calmar Ratio Rank: 9595
Calmar Ratio Rank
CRVS Martin Ratio Rank: 9191
Martin Ratio Rank

ATEYY
ATEYY Risk / Return Rank: 8888
Overall Rank
ATEYY Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
ATEYY Sortino Ratio Rank: 8686
Sortino Ratio Rank
ATEYY Omega Ratio Rank: 8383
Omega Ratio Rank
ATEYY Calmar Ratio Rank: 9191
Calmar Ratio Rank
ATEYY Martin Ratio Rank: 9191
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRVS vs. ATEYY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Corvus Pharmaceuticals, Inc. (CRVS) and Advantest Corp DRC (ATEYY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CRVSATEYYDifference
Sharpe ratioReturn per unit of total volatility

-0.13

Sortino ratioReturn per unit of downside risk

+2.79

Omega ratioGain probability vs. loss probability

1.61

1.29

+0.31

Calmar ratioReturn relative to maximum drawdown

5.46

4.06

+1.40

Martin ratioReturn relative to average drawdown

10.84

10.71

+0.13

CRVS vs. ATEYY - Sharpe Ratio Comparison

The current CRVS Sharpe Ratio is 1.72, which is comparable to the ATEYY Sharpe Ratio of 1.85. The chart below compares the historical Sharpe Ratios of CRVS and ATEYY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CRVS vs. ATEYY - Drawdown Comparison

The maximum CRVS drawdown since its inception was -96.97%, which is greater than ATEYY's maximum drawdown of -56.48%. Use the drawdown chart below to compare losses from any high point for CRVS and ATEYY.


Loading charts...

Drawdown Indicators


CRVSATEYYDifference

Max Drawdown

Largest peak-to-trough decline

-96.97%

-56.48%

-40.49%

Max Drawdown (1Y)

Largest decline over 1 year

-56.43%

-33.24%

-23.19%

Max Drawdown (3Y)

Largest decline over 3 years

-70.50%

-44.70%

-25.80%

Max Drawdown (5Y)

Largest decline over 5 years

-92.40%

-56.48%

-35.92%

Max Drawdown (10Y)

Largest decline over 10 years

-96.97%

-56.48%

-40.49%

Current Drawdown

Current decline from peak

-36.99%

-17.96%

-19.03%

Average Drawdown

Average peak-to-trough decline

-69.14%

-14.19%

-54.95%

Ulcer Index

Depth and duration of drawdowns from previous peaks

28.40%

12.57%

+15.83%

Volatility

CRVS vs. ATEYY - Volatility Comparison

The current volatility for Corvus Pharmaceuticals, Inc. (CRVS) is 10.26%, while Advantest Corp DRC (ATEYY) has a volatility of 31.05%. This indicates that CRVS experiences smaller price fluctuations and is considered to be less risky than ATEYY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CRVSATEYYDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.26%

31.05%

-20.79%

Volatility (6M)

Calculated over the trailing 6-month period

111.38%

58.17%

+53.21%

Volatility (1Y)

Calculated over the trailing 1-year period

179.42%

72.92%

+106.50%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

131.12%

54.23%

+76.89%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

111.17%

49.08%

+62.09%

Dividends

CRVS vs. ATEYY - Dividend Comparison

Neither CRVS nor ATEYY has paid dividends to shareholders.


PositionTTM2025202420232022202120202019201820172016
ATEYY
Advantest Corp DRC
0.00%0.11%0.22%0.00%0.00%0.00%0.00%0.00%0.00%1.18%1.24%
CRVS
Corvus Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

CRVS vs. ATEYY - Financials Comparison

This section allows you to compare key financial metrics between Corvus Pharmaceuticals, Inc. and Advantest Corp DRC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00B100.00B150.00B200.00B250.00B300.00B350.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
334.10B
(CRVS) Total Revenue
(ATEYY) Total Revenue
Please note, different currencies. CRVS values in USD, ATEYY values in JPY

Frequently Asked Questions


CRVS and ATEYY have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ATEYY has higher volatility (31.05%) compared to CRVS (10.26%). In terms of maximum drawdown, CRVS dropped -96.97% vs ATEYY's -56.48%.

ATEYY currently has the higher Sharpe Ratio (1.85 vs 1.72), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CRVS and ATEYY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer